These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19307790)

  • 21. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
    González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R
    J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study.
    Moro J; Almenar L; Martínez-Dolz L; Izquierdo M; Rueda J; Arnau MA; Agüero J; Sánchez-Lázaro I; Ortiz V; Salvador A
    Transplant Proc; 2007 Sep; 39(7):2365-7. PubMed ID: 17889191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation.
    Roland M; Gatault P; Doute C; Büchler M; Al-Najjar A; Barbet C; Chatelet V; Marlière JF; Nivet H; Lebranchu Y; Halimi JM
    Transpl Int; 2008 Jun; 21(6):523-30. PubMed ID: 18266773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function.
    De Simone P; Carrai P; Precisi A; Petruccelli S; Baldoni L; Balzano E; Ducci J; Caneschi F; Coletti L; Campani D; Filipponi F
    Transpl Int; 2009 Mar; 22(3):279-86. PubMed ID: 19054383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with proteinuria in renal transplant recipients treated with sirolimus.
    Liew A; Chiang GS; Vathsala A
    Transpl Int; 2009 Mar; 22(3):313-22. PubMed ID: 19054382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversible sirolimus-associated pneumonitis after heart transplantation.
    Hamour IM; Mittal TK; Bell AD; Banner NR
    J Heart Lung Transplant; 2006 Feb; 25(2):241-4. PubMed ID: 16446228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
    Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature.
    Weiner SM; Sellin L; Vonend O; Schenker P; Buchner NJ; Flecken M; Viebahn R; Rump LC
    Nephrol Dial Transplant; 2007 Dec; 22(12):3631-7. PubMed ID: 17611248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus.
    Kihm LP; Hinkel UP; Michael K; Sommerer C; Seckinger J; Morath C; Zeier M; Schwenger V
    Transplantation; 2009 Jul; 88(2):261-5. PubMed ID: 19623023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus: efficacy and safety in cardiac transplantation.
    Schaffer SA; Ross HJ
    Expert Opin Drug Saf; 2010 Sep; 9(5):843-54. PubMed ID: 20701555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study.
    Othman M; Kawar B; El Nahas AM
    Nephron Clin Pract; 2009; 113(1):c16-23. PubMed ID: 19590231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic kidney disease in children following lung and heart-lung transplantation.
    Benden C; Kansra S; Ridout DA; Shaw NL; Aurora P; Elliott MJ; Marks SD
    Pediatr Transplant; 2009 Feb; 13(1):104-10. PubMed ID: 19087230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients.
    Pons JA; Ramírez P; Revilla-Nuin B; Pascual D; Baroja-Mazo A; Robles R; Sanchez-Bueno F; Martinez L; Parrilla P
    Clin Transplant; 2009; 23(3):329-36. PubMed ID: 19210687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation.
    Abboud I; Porcher R; Robin M; de Latour RP; Glotz D; Socié G; Peraldi MN
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pericardial effusion coincident with sirolimus therapy: a review of Wyeth's safety database.
    Steele GH; Adamkovic AB; Demopoulos LA; Rothrock LC; Caulfield ME; Blum MD; Schubert CM; Hembekides DD; Singh AB
    Transplantation; 2008 Feb; 85(4):645-7. PubMed ID: 18347546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference.
    Rothenburger M; Zuckermann A; Bara C; Hummel M; Strüber M; Hirt S; Lehmkuhl H;
    J Heart Lung Transplant; 2007 Apr; 26(4):305-11. PubMed ID: 17403469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.
    Huyghe E; Zairi A; Nohra J; Kamar N; Plante P; Rostaing L
    Transpl Int; 2007 Apr; 20(4):305-11. PubMed ID: 17326771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.